Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 8/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.36 |
| ▸ | FAP | Q12884 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24260365 | 0.94 | XPNPEP1 (0.41) | XPNPEP1DPP4DPP7FAPKMT2A | |
| SCHEMBL24260443 | 0.92 | DPP4 (0.41) | XPNPEP1DPP4DPP7FAPKMT2A | |
| SCHEMBL24260359 | 0.90 | DPP4 (0.40) | XPNPEP1DPP4DPP7FAPKMT2A | |
| SCHEMBL24260380 | 0.90 | DPP4 (0.43) | XPNPEP1DPP4DPP7FAPKMT2A | |
| SCHEMBL24260406 | 0.86 | F2 (0.40) | XPNPEP1DPP4DPP7FAPKDM4E | |
| SCHEMBL24260120 | 0.85 | XPNPEP1 (0.37) | XPNPEP1DPP4DPP7FAPKDM4E | |
| SCHEMBL24260304 | 0.85 | DPP4 (0.38) | XPNPEP1DPP4DPP7FAP | |
| SCHEMBL24260148 | 0.84 | XPNPEP1 (0.38) | XPNPEP1DPP4DPP7FAPKDM4E | |
| SCHEMBL24260424 | 0.81 | POLB (0.39) | XPNPEP1DPP4DPP7FAPKMT2A | |
| SCHEMBL24260247 | 0.80 | XPNPEP1 (0.42) | XPNPEP1DPP4DPP7FAPHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820727-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-11254659-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | CENTREXION THERAPEUTICS CORPORATION (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820727-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | TRPV1, TRPV2, TRPV3 | XPNPEP1 1283/4885DPP4 99/4885DPP7 192/4885 |
| US-11254659-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | TRPV1, TRPA1, TRPV2 | XPNPEP1 2928/4885DPP4 746/4885DPP7 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.